Omjara tablets 150mg, manufactured by GlaxoSmithKline, contains Momelotinib hydrochloride (YJ code: 4291083F2029, standard: 150mg 1 tablet). This JAK1, JAK2, and ACVR1 inhibitor is specifically indicated for the treatment of intermediate or high-risk myelofibrosis with anemia, providing a dual benefit by addressing both disease symptoms and anemia.
Omjara tablets 150mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →
